Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director | December 15, 2016 | December 19, 2016 |
| Serina Therapeutics, Inc.AGE · Entity 9581 | Director | March 15, 2019 | March 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date December 15, 2016 · Filed December 19, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2026-12-15 | Direct | 31,250 |
Reported balance
After 2016-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-12-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting.
Serina Therapeutics, Inc.
Report date March 15, 2019 · Filed March 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2019-03-18 | IndirectRetirement Plans | 0 |
Reported balance
After 2019-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-15 · Sale · Disposed 50,000 · Balance 0 F1: Warrants held in retirement plans of companies controlled by Mr. Mauldin. |
Filing footnotes · ownership attribution and instrument terms
F1: Warrants held in retirement plans of companies controlled by Mr. Mauldin.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2019 Filed Mar 21, 2019 00:58 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | SaleWarrant to Purchase Common Stock · Derivative | 50,000 | $1.65 Strike: $2.50 | $82,500.00 |
DisclosureSEC source: 0001209191-19-020692 · doc4.xml · derivative · entry 1 MAULDIN JOHN F · CIK 0001522480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Retirement Plans Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-03-18 F1 · ownership.nature: Warrants held in retirement plans of companies controlled by Mr. Mauldin. Read SEC document |
| March 11, 2019 Filed Mar 14, 2019 00:53 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantOption to Pruchase Common Stock · Derivative | 65,000 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001209191-19-019311 · doc4.xml · derivative · entry 1 MAULDIN JOHN F · CIK 0001522480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-03-10 F1 · derivative.exercise_date: Options will become exercisable in four equal quarterly installments from the date of grant on March 11, 2019 provided that the grantee remains a director on the last day of the applicable calendar quarter. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:27 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 31,250 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001179022-16-000134 · edgar.xml · derivative · entry 1 MAULDIN JOHN F · CIK 0001522480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common stock · 31,250 shares Expires 2026-12-15 F1 · derivative.exercise_date: The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.